$AURA

Aura Biosciences, Inc.

CIK:0001501796|SEC Filings

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands

3 Months Ended

6 Months Ended

Jun. 30, 2026

Jun. 30, 2025

Jun. 30, 2026

Jun. 30, 2025

Operating Expenses:

Research and development

$ 30,749

$ 22,882

$ 58,709

$ 46,225

General and administrative

^[1]

17,320

5,731

24,226

11,423

Total operating expenses

48,069

28,613

82,935

57,648

Total operating loss

(48,069)

(28,613)

(82,935)

(57,648)

Other income (expense):

Interest income, including amortization and accretion income

2,307

1,678

3,497

3,271

Other income (expense)

154

(36)

155

(59)

Total other income

2,461

1,642

3,652

3,212

Loss before income taxes

(45,608)

(26,971)

(79,283)

(54,436)

Income tax provision, net

(29)

(48)

(39)

(66)

Net loss

$ (45,637)

$ (27,019)

$ (79,322)

$ (54,502)

Net loss per common share - basic

$ (0.48)

$ (0.47)

$ (0.98)

$ (1.01)

Net loss per common share - diluted

$ (0.48)

$ (0.47)

$ (0.98)

$ (1.01)

Weighted average common stock outstanding - basic

94,863,400

58,015,718

81,231,222

54,092,728

Weighted average common stock outstanding - diluted

94,863,400

58,015,718

81,231,222

54,092,728

Comprehensive loss:

Net loss

$ (45,637)

$ (27,019)

$ (79,322)

$ (54,502)

Other comprehensive income (loss):

Unrealized loss on marketable securities

(290)

(88)

(368)

(226)

Currency translation adjustment

(173)

(200)

(12)

Total other comprehensive loss

(463)

(80)

(568)

(238)

Total comprehensive loss

$ (46,100)

$ (27,099)

$ (79,890)

$ (54,740)

[1]	Includes depreciation expense directly allocated to respective activities.

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025	Dec. 31, 2025
Cash flows from operating activities:
Net loss			$ (79,322)	$ (54,502)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	$ 300	$ 300	534	577
Accretion income on marketable securities			(632)	(785)
Stock-based compensation expense			16,192	7,347
Other non-cash items			19	27
Non-cash lease expense			835	757
Changes in operating assets and liabilities:
Prepaid expenses and other assets			310	2,882
Other long-term assets			(668)	333
Accounts payable			698	(1,018)
Accrued expenses and other liabilities			423	910
Operating lease liabilities			(783)	(657)
Net cash used in operating activities			(62,394)	(44,129)
Cash flows from investing activities:
Purchases of property and equipment			(123)	(226)
Purchases of marketable securities			(256,014)	(9,984)
Maturities of marketable securities			85,000	60,000
Net cash provided by (used in) investing activities			(171,137)	49,790
Cash flows from financing activities:
Proceeds from exercise of stock options			136	2
Proceeds from exercise of warrants			123	0
Proceeds from issuance of common stock from follow-on offering, net of issuance costs			259,384	46,517
Proceeds from issuance of pre-funded warrants from follow-on offering, net of issuance costs			21,381	14,156
Proceeds from issuance of common stock warrants from follow-on offering, net of issuance costs			0	9,254
Repurchase of common stock, including transaction costs			(39,093)	0
Proceeds from ESPP purchases			121	96
Net cash provided by financing activities			242,052	70,025
Net increase in cash, cash equivalents and restricted cash			8,521	75,686
Effect of exchange rate changes on cash and cash equivalents			(200)	(12)
Cash, cash equivalents and restricted cash at beginning of period			60,283	32,461	$ 32,461
Cash, cash equivalents and restricted cash at end of period	$ 68,604	$ 108,135	68,604	108,135	$ 60,283
Supplemental disclosure of cash flow information:
Purchases of property and equipment in accounts payable and accrued expenses and other liabilities			$ 7	$ 0

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 67,836	$ 59,515
Marketable securities	256,004	84,726
Prepaid expenses and other current assets	5,188	5,498
Total current assets	329,028	149,739
Restricted cash and deposits	768	768
Right-of-use assets - operating lease	14,993	15,828
Other long-term assets	1,139	471
Property and equipment, net	2,201	2,624
Total Assets	348,129	169,430
Current liabilities:
Accounts payable	2,254	1,549
Short-term operating lease liability	3,292	3,243
Accrued expenses and other current liabilities	14,014	13,591
Total current liabilities	19,560	18,383
Long-term operating lease liability	13,302	14,134
Total Liabilities	32,862	32,517
Commitments and Contingencies (Note 12)
Stockholders' Equity:
Common stock, $0.00001 par value, 150,000,000 authorized at June 30, 2026 and December 31, 2025, and 103,480,053 and 63,587,777 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively	1
Additional paid-in capital	914,769	617,433
Treasury stock, at cost, 6,922,870 shares held at June 30, 2026 and no shares held at December 31, 2025	(39,093)	0
Accumulated deficit	(559,740)	(480,418)
Accumulated other comprehensive loss	(670)	(102)
Total Stockholders' Equity	315,267	136,913
Total Liabilities and Stockholders' Equity	$ 348,129	$ 169,430